Enfuvirtide; T-20 is a synthetic 36-amino-acid peptide and the first FDA-approved HIV-1 fusion inhibitor, designed to block viral entry into host cells by targeting the gp41 glycoprotein on the HIV-1 envelope. It binds to the hydrophobic heptad repeat 2 (HR2) domain of gp41, preventing the conformational changes necessary for viral and cellular membrane fusion, thus inhibiting HIV-1 infection. Clinically, Enfuvirtide is administered subcutaneously as part of combination antiretroviral therapy (cART) for treatment-experienced patients with multidrug-resistant HIV-1, reducing viral load and improving CD4+ cell counts. In pharmacological research, it serves as a tool to investigate viral entry mechanisms, membrane fusion dynamics, and the development of novel anti-HIV agents. Its unique mechanism of action highlights its role in combating drug-resistant HIV and underscores the importance of targeting viral-host interactions in antiviral therapy.

Chemical Formula: C204H301N51O64

Molecular Weight: 4492.01

Sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2

Purity: From crude to 98%

If there are no products available iwth the required purity and quantity, please inform us of your specifications and send an email to sales@alanscientific.com

Our representitives will respond within 24 hours

Research Use Only